1. Home
  2. COCP vs BNC Comparison

COCP vs BNC Comparison

Compare COCP & BNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COCP
  • BNC
  • Stock Information
  • Founded
  • COCP 2006
  • BNC N/A
  • Country
  • COCP United States
  • BNC United States
  • Employees
  • COCP N/A
  • BNC N/A
  • Industry
  • COCP Biotechnology: Pharmaceutical Preparations
  • BNC Industrial Machinery/Components
  • Sector
  • COCP Health Care
  • BNC Industrials
  • Exchange
  • COCP Nasdaq
  • BNC Nasdaq
  • Market Cap
  • COCP 15.4M
  • BNC 13.7M
  • IPO Year
  • COCP N/A
  • BNC N/A
  • Fundamental
  • Price
  • COCP $1.60
  • BNC $27.34
  • Analyst Decision
  • COCP Strong Buy
  • BNC
  • Analyst Count
  • COCP 1
  • BNC 0
  • Target Price
  • COCP $6.00
  • BNC N/A
  • AVG Volume (30 Days)
  • COCP 169.4K
  • BNC 1.0M
  • Earning Date
  • COCP 08-22-2025
  • BNC 08-22-2025
  • Dividend Yield
  • COCP N/A
  • BNC N/A
  • EPS Growth
  • COCP N/A
  • BNC N/A
  • EPS
  • COCP N/A
  • BNC N/A
  • Revenue
  • COCP N/A
  • BNC $3,478,254.00
  • Revenue This Year
  • COCP N/A
  • BNC N/A
  • Revenue Next Year
  • COCP N/A
  • BNC N/A
  • P/E Ratio
  • COCP N/A
  • BNC N/A
  • Revenue Growth
  • COCP N/A
  • BNC 10.08
  • 52 Week Low
  • COCP $1.12
  • BNC $5.60
  • 52 Week High
  • COCP $3.26
  • BNC $82.88
  • Technical
  • Relative Strength Index (RSI)
  • COCP 46.18
  • BNC N/A
  • Support Level
  • COCP $1.56
  • BNC N/A
  • Resistance Level
  • COCP $2.19
  • BNC N/A
  • Average True Range (ATR)
  • COCP 0.14
  • BNC 0.00
  • MACD
  • COCP -0.02
  • BNC 0.00
  • Stochastic Oscillator
  • COCP 6.35
  • BNC 0.00

About COCP Cocrystal Pharma Inc.

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

Share on Social Networks: